课题基金 / 基金详情

Solute carrier family 26 member 9 (SLC26A9) and cystic fibrosis transmembrane conductance regulator (CFTR) disruptors as novel therapeutics for cystic fibrosis.

Solute carrier family 26 member 9 (SLC26A9) and cystic fibrosis transmembrane conductance regulator (CFTR) disruptors as novel therapeutics for cystic fibrosis.
溶质载体家族 26 成员 9 (SLC26A9) 和囊性纤维化跨膜电导调节剂 (CFTR) 干扰剂作为囊性纤维化的新型疗法。
批准号：
350174
负责人：
Sato Yukiko
金额：
$1.27万
依托单位：
McGill University
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-12-01 至 2016-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=350174&lang=en
关键词：
Cftr Chronic Obstructive Pulmonary Disease Cystic Fibrosis High-Throughput Drug Screen Ion Channel Activator Lung Disease Protein Trafficking Protein-Protein Disruptor Protein-Protein Interaction Slc26a9

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
上皮细胞离子通道和转运体维持肺内环境的稳定，而囊性纤维化跨膜电导调节器(CFTR)阴离子通道功能丧失突变，减少呼吸道分泌，导致囊性纤维化(CF)。这是
英文摘要
Epithelial ion channels and transporters maintain pulmonary homeostasis and a loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel reduce airway secretion and cause the disease cystic fibrosis (CF). Th
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金